Bank of Nova Scotia Trust’s GSK GSK Stock Holding History

Bank of Nova Scotia Trust’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,133	Closed	-$932K	–	133
2022 Q2	$932K	Sell	17,133 -148	-0.9%	-$8.17K	0.1%	77
2022 Q1	$941K	Buy	17,281 +175	+1%	+$9.51K	0.08%	81
2021 Q4	$943K	Sell	17,106 -218	-1%	-$11.3K	0.08%	83
2021 Q3	$827K	Buy	17,324 +6	+0%	+$301	0.07%	84
2021 Q2	$862K	Sell	17,318 -1,206	-7%	-$57.9K	0.08%	82
2021 Q1	$826K	Buy	18,524 +24	+0.1%	+$1.09K	0.08%	80
2020 Q4	$851K	Sell	18,500 -34	-0.2%	-$1.56K	0.09%	76
2020 Q3	$872K	Buy	18,534 +78	+0.4%	+$3.91K	0.11%	70
2020 Q2	$941K	Buy	+18,456	New	+$947K	0.14%	62
2017 Q4	–	Sell	-5,052	Closed	-$256K	–	234
2017 Q3	$256K	Buy	5,052 +741	+17%	+$37.6K	0.03%	124
2017 Q2	$232K	Sell	4,311 -32	-0.7%	-$1.71K	0.03%	115
2017 Q1	$229K	Buy	+4,343	New	+$220K	0.03%	112

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of Nova Scotia Trust's GSK Position: Q3 2022 in Review

Bank of Nova Scotia Trust sold out of GSK (GSK) in Q3 2022, closing a stake of 17,133 shares — an estimated $932K sold.

Bank of Nova Scotia Trust first reported a position in GSK in Q1 2017 and held it in 12 quarters. The position peaked at $943K in Q4 2021. 743 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Bank of Nova Scotia Trust reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Bank of Nova Scotia Trust sold 17,133 GSK shares in Q3 2022, an estimated $932K.
Bank of Nova Scotia Trust first reported a position in GSK in Q1 2017 and held it in 12 quarters.
Bank of Nova Scotia Trust's GSK position peaked at $943K in Q4 2021.
743 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Bank of Nova Scotia Trust's 13F filing for Q3 2022, filed 10 Nov 2022.